Skip to Content


Active Substance: irbesartan
Common Name: irbesartan
ATC Code: C09CA04
Marketing Authorisation Holder: Pharmathen S.A.
Active Substance: irbesartan
Status: Withdrawn
Authorisation Date: 2012-04-13
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Agents acting on the renin-angiotensin system

Therapeutic Indication

Sabervel is indicated in adults for the treatment of essential hypertension.

It is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.

The marketing authorisation for Sabervel has expired following the marketing authorisation holder's decision not to apply for a renewal.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.